About
BioActor develops proprietary health ingredients for use in functional foods, medical nutrition and dietary supplements. All these ingredients address chronic health concerns, such as diabetes,osteoporosis, cardiovascular disease, that would benefit from preventative measures through the diet. BioActor's product development strategy relies on three simple tenets: a new health ingredient must be based on a patentable scientific discovery; it must be food grade from a natural and renewable source; and its health effect must be clinically proven. BioActor's first product, BONOLIVE, a first in class bone health ingredient that is clinically proven to stimulate bone producing cells, is a great example of this strategy and will be launched in the USA this year. BioActor successfully implemented its product development strategy by establishing alliances with top nutrition research institutes (e.g. INRA, CSIC, Maastricht University, UCL, Ghent University) and by establishing production partner
Position in the VCSift Database
- • 3,884 investors in VCSift focus on the healthtech sector.
- • 18 investors are based in Maastricht, Limburg, The Netherlands.
Data sourced from 410,343 investor profiles. Updated July 2026.
Investment Focus
- Sectors
- healthtech biotech
- Location
- Maastricht, The Netherlands
Contact Information
Find more investors like BioActor
Search Investors